Absolute quantification without the standard curve

Digital PCR (dPCR) partitions a bulk PCR reaction into thousands of picoliter-scale reactions — each containing one or just a few DNA molecules. By simply counting positive partitions, the original targets can be precisely quantified without needing a standard curve.

Digital PCR provides unparalleled confidence in applications ranging from rare target identification, copy-number-variation (CNV), gene expression and more.

Highlighted Research Areas

Oncology

From routine biomarker testing to long-term patient monitoring, digital PCR (dPCR) with the Absolute Q System enables high confidence in target identification — down to just a few target molecules per reaction. Learn how Absolute Q leverages low false positives and multi-color multiplexing to enhance precision medicine with a one-step, walk-away workflow.

Infectious Disease​​

Digital PCR is ideal for identifying rare sequences that are lost in the background as is often the case for infectious disease analysis. Furthermore, Digital PCR reliably outperforms qPCR in ultra-rare target detection and is more tolerant to potential PCR inhibitors. Learn more about how the Absolute Q’s 4-color multiplexing and 90-minute workflow can be leveraged for infectious disease applications.

Reproductive Health​​

Digital PCR is ideal for identifying rare sequences that are lost in the background as is often the case for infectious disease analysis. Furthermore, Digital PCR reliably outperforms qPCR in ultra-rare target detection and is more tolerant to potential PCR inhibitors. Learn more about how the Absolute Q’s 4-color multiplexing and 90-minute workflow can be leveraged for infectious disease applications.

Highlighted Applications

  • All
  • Infectious Disease
  • Oncology
  • Reproductive Health
All
  • All
  • Infectious Disease
  • Oncology
  • Reproductive Health

Combinati |Q| SARS-CoV-2 Triplex Assay for sensitive detection of viral RNA targets​

The COVID-19 pandemic has drawn heightened concern, with over eleven million positive SARS-CoV-2 cases confirmed worldwide by July 2020. 1 RT-qPCR currently serves as the clinical standard for the diagnosis of COVID-19.

LEARN MORE

Discriminatory 11-Plex Assay Designed to Monitor Estrogen Receptor Mutations Using a Novel, Melt-Analysis Capable Digital PCR Platform​

In a large fraction of ER+/HER2- metastatic breast cancer (MBC), treatment with aromatase inhibitors fails due to emerging resistance. A
key mechanism of this resistance is associated with a set of missense mutations in the gene encoding for the estrogen receptor (ESR1). We
have developed a multiplex, quantitative, Research Use Only assay for the detection and identification of 11 ESR1 single nucleotide polymorphisms (SNPs) and the ESR1 gene in a single reaction, using patented, melt-based chemistry and an innovative digital PCR (dPCR) system.

LEARN MORE

Fully Integrated Single Instrument Imaging-based Digital PCR Platform

Digital PCR (dPCR) has gained popularity in recent years for cancer research such as rare
mutation detection, minimal residual disease, treatment selection, and recurrence monitoring. However, currently available technologies suffer from several limitations such as tedious workflow, long time-to-result, poor multiplexity, and inconsistent reagent digitization, which has severely hindered its broad adoption. We have designed and manufactured a dPCR platform that is capable of consistent sample digitization, thermal cycling and simultaneous interrogation of 20,000 partitions with walk-away workflow.

LEARN MORE

Combinati |Q| SARS-CoV-2 Digital PCR Test Protocol

The Combinati Absolute Q provides a walkaway digital PCR workflow. Considering all steps including reverse transcription are completed in under 90 minutes, the Absolute Q provides the fastest time-to answer digital PCR workflow for precise quantification of viral reference material.

LEARN MORE

1-Step RT-dPCR in under 80 Minutes on the Combinati Absolute Q

The Absolute Q dPCR platform and its 80-minute 1-step RT-dPCR technology have broad implications for characterizing infectious diseases beyond COVID-19. The versatile platform can be adapted to a wide range of nucleic acid detection applications requiring absolute quantification.

LEARN MORE

Experiment Flexibility with the Combinati™ Absolute Q Digital PCR Platform

Microfluidic Array Partitioning (MAP) technology utilizes fixed microchamber arrays and positive pneumatic pressure to partition reagents and perform digital PCR, instead of using fluid-shearing to generate droplets.

LEARN MORE